Julia Karow, Managing Editor at GenomeWeb; Robert Green, Director of Genomes2People and Co-Chair of the International Consortium on Newborn Sequencing (ICoNS); Wendy Chung, Chair of Pediatrics in Medicine at Boston Children’s Hospital and leader of the Guardian Study; and James Buchanan, Senior Lecturer in Health Economics at Queen Mary University in London, discuss takeaways and … Continued
Economics/cost analyses in genomics
“We might think that science and money have nothing to do with each other, but whether it’s video games, consumer DNA kits, or even the concrete we build with, the connections are everywhere. Listen to Dr. Mitu Khandaker, Dr. John Orr, and Dr. Jason Vassy explore what happens when research and commercial interests collide.”
“The cost of sequencing itself is already comparable to a lot of other diagnostic tests regularly used in medicine,” Kurt Christensen, PhD said. Besides: “What really moves the needle on cost effectiveness isn’t the costs — it’s the benefits.”
Under the four-year collaboration, experts in genomic medicine from Harvard and Brigham and Women’s will help guide Sanford researchers in using and interpreting data collected through the Sanford Chip, a $49 pharmacogenomic test to identify genetic risk factors for medication use and more accurately prescribe medications.
Spring saw accomplishments by team members through numerous projects. G2P officially kicked-off the PeopleSeq consortium in Boston this January! Our very own, Carrie Blout, MS, CGC, was one of 86 Partner’s individuals awarded the Partners In Excellence Award.
Parents and clinicians have their own ideas about newborn genome sequencing. Dr. Robert Green, principal investigator of the BabySeq Project, shares a detailed analysis of the results from the study and his thoughts on the utility of genomic sequencing for newborns in clinical care.
The true costs of genome sequencing don’t end with the technical production of A’s, T’s, C’s and G’s, and they don’t even end with the molecular interpretation of a few dozen or even a few hundred genes.
Whole genome sequencing (WGS) can help identify rare blood-type donors and transfusion recipients who may be at risk of adverse reactions from red blood cell antigen mismatches.
A study of two groups of 100 patients found no evidence that whole genome sequencing increases downstream healthcare costs. The story begins on Page 12.
Spring saw accomplishments by team members and new advances in direct-to-consumer testing. Dr. Kurt Christensen provides compelling detail about econogenomics cost and benefits to genetic sequencing, and Megan Maxwell discusses genetic counseling and the MilSeq project on a podcast.
The second piece of a 2-part blog series authored by Dr. Robert C. Green. An early study found no problems related to unnecessary or harmful medical follow-ups after healthy people received their genome sequencing results. To read the first piece, visit: https://medium.com/@genomes2people/genome-sequencing-for-healthy-people-will-it-be-helpful-b984b94e3d3f
Findings in whole-genome sequencing don’t lead to excessive follow-up testing, an early study found.
“Whole genome sequencing is coming of age, but there’s fear that with these advancements will come rocketing health care costs,” said lead author Kurt Christensen, MPH, PhD, an instructor of medicine in the Division of Genetics at BWH. “Our pilot study is the first to provide insights into the cost of integrating whole genome sequencing … Continued
A pilot study found no significant increases in healthcare costs among people who received whole-genome sequencing results along with a family history report.
The first piece of a 2-part blog series authored by Dr. Robert C. Green. Early results suggest that yes, whole genome sequencing may very well be substantially helpful to a significant number of healthy patients. To read the second piece, visit: https://medium.com/@genomes2people/genome-sequencing-for-healthy-people-will-it-be-harmful-d915cc08e634
Winter highlights include Dr. Robert Green’s interview with Rob Reid on the pros and cons to genetic sequencing, G2P team members’ participation in the American Society of Human Genetics (ASHG) conference, and our Understand Your Genome Educational Event in Boston.
A blog post authored by Dr. Robert Green discussing the benefits and challenges that people and health professionals are faced with when dealing with genetic testing and screening. Here, he addresses ethical issues and potential complications alongside beneficial factors that deal genome testing.
An overview and summary of the main projects that are being conducted within the G2P program, both past and present. This article also includes the progract managers and research assistants on each major project.